← Eichor
Study identifier: NCT07112599 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis

Condition: Prostate Cancer · Lymph Node Cancer Metastatic · Artificial Intelligence (AI)  ·  Sponsor: Anhui Medical University

PhaseN/A
Planned participants2000
Who can joinMale, 50 Years to no upper limit
Healthy volunteersNo

About this study

The pathological-omics and imaging-omics in this study are combined to construct an artificial intelligence (AI) model that can predict whether high-risk prostate cancer patients may have lymph node metastasis. The model determines whether the patient has lymph node metastasis based on the MRI results and the pathological section image information of the case combined with clinical data before radical resection of the prostate. This study is a multicenter, prospective clinical study to verify the model's ability to predict whether high-risk prostate cancer patients may have lymph node metastasis.

This description comes directly from the study's public registry record.

Talk to the study team

Sheng Tai  ·  +86 18355159268  ·  taisheng@ahmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Science and Technology Institute, Anhui Medical UniversityHefei, Anhui, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07112599